Amendments to the Claims:

Please amend the claims as follows:

1-60. (cancelled)

61. (currently amended) A ~~lipid~~ liposomal formulation containing a compound that is:

(i) a diester of a compound of formula A



A

where:

each ester is 1-25C;

YCO is γ-glu or β-asp;

G* is phenylglycine;

Z is CH_2, O or S; and

X is a hydrocarbon radical which is alkyl (6-8C), benzyl, or naphthyl;

or a pharmaceutically acceptable salt thereof; or

(ii) a compound of formula I



I

where:

R_1 and R_2 are each independently linear or branched alkyl (1-25C), cycloalkyl (6-25C), heterocycle (6-25C), ether or polyether (3-25C), or R_1 and R_2 together have 2-20 C atoms and form a macrocycle with the remainder of formula I; and

X is as defined above for formula A;

or a pharmaceutically acceptable salt thereof;

where the lipids of the ~~lipid~~ liposomal formulation ~~are~~ consist of egg phosphatidylcholine

and egg phosphatidylglycerol in a ratio of 0.75-1.25:0.75-1.25 by weight and the ratio of lipids to compound is 3.5-4.5:0.5-1.5 by weight.

62. (currently amended) The ~~lipid~~ liposomal formulation of claim 61 where the compound is γ-glutamyl-S(benzyl)cysteinyl-R-phenylglycine diethyl ester or a pharmaceutically acceptable salt thereof.

63. (cancelled)

64. (currently amended) The ~~lipid~~ liposomal formulation of claim ~~63~~ 61 where the ratio of lipids to compound is 3:1-6:1 by weight.

65. (canceled)

66. (currently amended) The ~~lipid~~ liposomal formulation of claim 61, having

(i) at least 50% degree of encapsulation of the compound; and

(ii) an average vesicle size of 50-2000 nm.

67. (currently amended) The ~~lipid~~ liposomal formulation of claim 66 where the degree of encapsulation is above 80%.

68. (currently amended) The ~~lipid~~ liposomal formulation of claim 66 where the vesicle size is 400-600 nm.

69. (currently amended) The ~~lipid~~ liposomal formulation of claim 61 which ~~is a liposomal formulation composed~~ consists essentially of 1 part compound, 2 parts egg phosphatidylcholine, 2 parts egg phosphatidylglycerol, and 7 parts sucrose by weight.

70. (currently amended) The ~~lipid~~ liposomal formulation of claim 69 which ~~comprises liposomes composed~~ consists essentially of 1 part γ-glutamyl-S(benzyl)cysteinyl-R-phenylglycine diethyl ester or a pharmaceutically acceptable salt thereof, 2 parts egg phosphatidylcholine, 2 parts egg phosphatidylglycerol, and 7 parts sucrose by weight.

71. (currently amended) The ~~lipid~~ liposomal formulation of claim 70 which comprises lyophilized liposomes ~~composed~~ consisting essentially of 1 part γ-glutamyl-S(benzyl)cysteinyl-R-phenylglycine diethyl ester or a pharmaceutically acceptable salt thereof, 2 parts egg phosphatidylcholine, 2 parts egg phosphatidylglycerol, and 7 parts sucrose by weight.

72. (currently amended) A method of preparing a ~~lipid~~ liposomal formulation containing a compound that is:

(i) a diester of a compound of formula A



A

where:

each ester is 1-25C;

YCO is γ-glu or β-asp;

G* is phenylglycine;

Z is CH_2, O or S; and

X is a hydrocarbon radical which is alkyl (6-8C), benzyl, or naphthyl;

or a pharmaceutically acceptable salt thereof; or

(ii) a compound of formula I



I

where:

R_1 and R_2 are each independently linear or branched alkyl (1-25C), cycloalkyl (6-25C), heterocycle (6-25C), ether or polyether (3-25C), or R_1 and R_2 together have 2-20 C atoms and form a macrocycle with the remainder of formula I; and

X is as defined above for formula A;

or a pharmaceutically acceptable salt thereof;

which method comprises formulating the compound in a ~~lipid~~ liposomal composition

where the lipids of the ~~lipid~~ liposomal formulation ~~are~~ consist of egg phosphatidylcholine and egg phosphatidylglycerol in a ratio of 0.75-1.25:0.75-1.25 by weight and the ratio of lipids to compound is 3.5-4.5:0.5-1.5 by weight.

73. (previously presented) The method of claim 72 where the compound is γ-glutamyl-S(benzyl)cysteinyl-R-phenylglycine diethyl ester or a pharmaceutically acceptable salt thereof.

74. (cancelled)

75. (previously presented) The method of claim 72, further comprising extrusion.

76. (previously presented) The method of claim 72, further comprising lyophilization.

77. (previously presented) The method of claim 72 which comprises dissolving 1 part γ-glutamyl-S(benzyl)cysteinyl-R-phenylglycine diethyl ester or a pharmaceutically acceptable salt thereof, 2 parts egg phosphatidylcholine, and 2 parts egg phosphatidylglycerol in ethanol/water, injecting the solution into water containing 7 parts sucrose, and extruding to form a liposomal formulation.

78. (previously presented) The method of claim 77 which comprises dissolving 1 part γ-glutamyl-S(benzyl)cysteinyl-R-phenylglycine diethyl ester or a pharmaceutically acceptable salt thereof, 2 parts egg phosphatidylcholine, and 2 parts egg phosphatidylglycerol in ethanol/water, injecting the solution into water containing 7 parts sucrose, extruding to form a liposomal formulation, and lyophilizing the liposomal formulation to form lyophilized liposomes.

79. (currently amended) A ~~lipid~~ liposomal formulation prepared by the method of claim 77.

80. (currently amended) A ~~lipid~~ lyophilized liposomal formulation prepared by the method of claim 78.

81. (currently amended) A method for modulating hematopoiesis or protecting against the destructive effects of chemotherapy comprising administering to a subject in need thereof a ~~lipid~~ liposomal formulation according to any one of claims 61, 62, 64, 66 to 71, 79, and 80.